lncRNA TUG1 promotes proliferation and differentiation of osteoblasts by regulating the miR-545-3p/CNR2 axis.
Journal
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
ISSN: 1414-431X
Titre abrégé: Braz J Med Biol Res
Pays: Brazil
ID NLM: 8112917
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
03
2020
accepted:
03
07
2020
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Osteoblast differentiation is an effective way to promote bone formation. Long non-coding RNA taurine upregulated 1 (TUG1) has been identified as a crucial modulator of multiple biological processes. This study was designed to investigate the function of TUG1 in the proliferation and differentiation of osteoblast precursor cells hFOB1.19. In this study, we found that TUG1 promoted hFOB1.19 cell proliferation, while TUG1 knockdown hindered cell proliferation. TUG1 and cannabinoid receptor 2 (CNR2) were upregulated, while miR-545-3p was down-regulated in hFOB1.19 cells undergoing osteoblastic differentiation. TUG1 induced osteoblast differentiation by increasing alkaline phosphatase (ALP) activity and the expression of osteoblastic differentiation markers. TUG1 was a sponge of miR-545-3p and regulated osteoblastic differentiation by modulating miR-545-3p. Moreover, miR-545-3p directly targeted CNR2 and restored the effect of CNR2 on osteoblastic differentiation. In conclusion, TUG1 accelerated the proliferation and differentiation of osteoblasts by sponging miR-545-3p and increasing CNR2 expression, which might provide a new biomarker for bone diseases.
Identifiants
pubmed: 33053117
pii: S0100-879X2020001100611
doi: 10.1590/1414-431X20209798
pmc: PMC7552904
pii:
doi:
Substances chimiques
CNR2 protein, human
0
MIR545 microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
Receptor, Cannabinoid, CB2
0
TUG1 long noncoding RNA, human
0
Taurine
1EQV5MLY3D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e9798Références
Biomed Pharmacother. 2018 Jan;97:1645-1653
pubmed: 29793327
Int J Mol Sci. 2016 Dec 27;18(1):
pubmed: 28035992
Int J Cardiol. 2017 Sep 15;243:404-412
pubmed: 28522163
Int J Oncol. 2019 Apr;54(4):1317-1326
pubmed: 30720136
Biomed Pharmacother. 2018 Nov;107:338-346
pubmed: 30098551
Front Endocrinol (Lausanne). 2018 Oct 04;9:587
pubmed: 30349507
Annu Rev Pharmacol Toxicol. 2011;51:25-43
pubmed: 20809797
Biochem Biophys Res Commun. 2019 Sep 10;517(1):103-110
pubmed: 31327495
Prog Neurobiol. 2001 Apr;63(5):569-611
pubmed: 11164622
Trends Mol Med. 2014 Aug;20(8):449-59
pubmed: 25008556
Nat Rev Endocrinol. 2019 Nov;15(11):651-665
pubmed: 31462768
Br J Pharmacol. 2008 Jan;153(2):182-8
pubmed: 18071301
Pharmacol Res. 2017 May;119:391-403
pubmed: 28274851
Nat Rev Endocrinol. 2012 Jan 31;8(4):212-27
pubmed: 22290358
Mol Cancer. 2011 Apr 13;10:38
pubmed: 21489289
J Endocrinol Invest. 2005;28(10 Suppl):8-13
pubmed: 16550716
J Cell Mol Med. 2018 Dec;22(12):6134-6147
pubmed: 30338912
Biomed Pharmacother. 2018 Dec;108:347-354
pubmed: 30227328
J Cancer Res Clin Oncol. 2018 Jan;144(1):39-52
pubmed: 28993942
Differentiation. 2019 Sep - Oct;109:9-15
pubmed: 31352121
Int J Biochem Cell Biol. 2008;40(9):1659-63
pubmed: 17656144
Int J Mol Sci. 2018 Apr 27;19(5):
pubmed: 29702599
Int J Biochem Cell Biol. 2015 Aug;65:20-31
pubmed: 25997875
Biomed Pharmacother. 2019 Dec;120:109378
pubmed: 31541885
Exp Ther Med. 2018 Jan;15(1):357-364
pubmed: 29250156
Oncol Lett. 2019 Nov;18(5):4393-4402
pubmed: 31611948
Nat Rev Endocrinol. 2013 May;9(5):288-95
pubmed: 23358353
Annu Rev Pathol. 2011;6:121-45
pubmed: 20936937
Aging Cell. 2017 Oct;16(5):1051-1061
pubmed: 28752643
Cardiovasc Res. 2018 Jan 1;114(1):168-179
pubmed: 29016735
J Cell Mol Med. 2019 Sep;23(9):6140-6153
pubmed: 31304676
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4584-4590
pubmed: 31210284
Lancet. 2011 Apr 9;377(9773):1276-87
pubmed: 21450337